Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis
Anti-tumor necrosis factor-alpha (anti-TNF-α) monoclonal antibodies are used in patients with inflammatory bowel disease . Demyelinating neuropathies are increasingly reported among patients treated with these agents . Multifocal motor neuropathy (MMN) is an asymmetric motor neuropathy with multifocal motor conduction blocks, and anti-GM1 antibodies found in 50% of cases . MMN can rarely occur as an adverse event of anti-TNF-α treatment, mainly associated to infliximab [2, 4]. We report a case of a 29-year-old Caucasian man with a 5-year history of ulcerative colitis (UC) in treatment with adalimumab twice monthly. After 6 months of treatment, the patient developed acute left hand weakness spontaneously recovered after 3 weeks. 2 months later, 2 days after adalimumab administration, he presented a new episode of left hand weakness. The neurological examination revealed weakness of left wrist extensors and finger extensors (MRC 3/5), without sensory alterations....
Compliance with ethical standards
This letter has been written in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Specific national laws have been observed.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- 1.Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA et al (2009) Biologics for rheumatoid arthritis: an overview of cochrane reviews. Cochrane Database Syst Rev 7(4):CD007848Google Scholar